Invivoscribe granted mutation detection license from Takara Bio
SHIGA, Japan—Takara Bio Inc. has granted Invivoscribe Technologies Inc. licenses to facilitate and conduct patent-covered tests for the presence of internal tandem duplication (ITD) mutations in the FLT3 gene. These mutations are known markers for refractory acute myeloid leukemia (AML) that appear in roughly one-third of AML cases and are associated with poor prognoses. Per the terms of the agreement, Invivoscribe Technologies will receive Japanese licenses to produce and sell in-vitro diagnostic products for FLT3/ITD detection exclusively, provide testing services for FLT3/ITD detection non-exclusively and produce and sell research reagent products for FLT3/ITD detection co-exclusively with Takara Bio. The agreement follows the exclusive worldwide (excluding Japan) license Invivoscribe Technologies received from Takara Bio in 2006 to use its patented detection method of FLT3/ITD mutation.